Cambinol is a cell-permeable SIRT1 and SIRT2 inhibitor with substrate-competitive activity, also functioning as a brain-penetrant neutral sphingomyelinase (N-SMase) inhibitor. It induces apoptosis in BCL6-expressing lymphoma cells via p53 and BCL6 hyperacetylation and is used in oncology and neurology research, including in vivo studies on exosome biology and cancer models.